NPC warns state drug price caps could hurt access and reimbursement

A National Pharmaceutical Council commentary in the American Journal of Managed Care warns that state upper payment limits could disrupt coverage, raise cost sharing and squeeze pharmacies and providers. The analysis comes as several states move at different speeds toward drug price caps, with no limits yet in effect.

Why it matters: - Upper payment limits could change how patients access prescription drugs, how much they pay, and whether pharmacies and providers can afford to keep stocking certain medicines. - The National Pharmaceutical Council says the policy risks vary by state and could ripple through formularies, reimbursement systems and local drug access.

What happened: - National Pharmaceutical Council researchers published a commentary in the American Journal of Managed Care on the potential consequences of upper payment limit implementation. - The analysis focuses on state prescription drug affordability boards, or PDABs, as more states consider or move toward drug price caps. - The commentary says four states have PDABs with authority to set upper payment limits: Colorado, Maryland, Minnesota and Washington. - No upper payment limits are in effect. - Colorado and Maryland PDABs have voted to implement upper payment limits for several drugs, but the limits have not taken effect. - A federal judge blocked a Colorado state panel from capping the price of an arthritis and autoimmune treatment. - Minnesota and Washington are in different stages of moving toward upper payment limit setting. - Virginia and Illinois have debated legislation to create new PDABs with upper payment limit authority.

The details: - A PDAB is a state board created to address prescription drug costs. - Supporters often say PDABs are meant to improve access to affordable medicines. - Some PDABs also have authority to set upper payment limits, which are maximum reimbursement amounts for certain payers. - An upper payment limit caps what a payer reimburses but does not lower what pharmacies and providers pay to acquire a drug. - An upper payment limit does not require coverage or guarantee lower out-of-pocket costs. - NPC says courts are still evaluating whether PDABs can legally set upper payment limits. - The analysis compared current access to 14 PDAB-selected drugs across the four states with UPL authority and states without UPLs. - NPC found state-specific risks to patient access, including weaker formulary coverage, higher cost sharing and more utilization management. - UPLs could lead payers to remove drugs from formularies, move them to higher cost-sharing tiers or impose stricter utilization management. - For pharmacies and providers, UPLs could create uncertainty around reimbursement and acquisition costs. - Reimbursement could fall below acquisition cost because the payer cap does not change what pharmacies and providers pay to buy the drug. - Smaller community-based and rural pharmacies and providers with tighter margins could be most exposed. - Some pharmacies and providers could limit or stop stocking drugs subject to UPLs.

Between the lines: - The commentary argues that government price-setting can create tradeoffs that are not always visible when policy is first adopted. - NPC points to federal price-setting efforts, including the Inflation Reduction Act drug negotiation program, as a cautionary example. - Early evidence from that program suggests limited cost-sharing relief alongside access risks when payers shift drugs or alternatives onto less favorable tiers or add utilization management. - NPC also cites a Congressional Budget Office analysis suggesting the Inflation Reduction Act cost more than originally projected. - The broader warning is that price caps may bring the same kinds of uncertainty seen in other government pricing efforts without clear patient benefits.

What's next: - States considering PDABs and upper payment limits are likely to keep testing the policy in court and in legislatures. - More legal challenges could shape whether existing PDAB authority survives and how far states can go on reimbursement caps. - The eventual impact on patient access and state health systems will depend on whether upper payment limits actually take effect and how payers respond.

The bottom line: - NPC’s message is that upper payment limits may look like a cost-control tool, but they could also disrupt access, reimbursement and drug availability without guaranteeing lower patient costs. - More information: NPC's website